In November 2019, Kinnov launches pivotal phase 2 trial in alcohol addiction, “Cocktail”.
Kinnov Therapeutics was granted 2.5 M€ by European Commission on 1 October 2019 (Horizon 2020 program)
Kinnov Therapeutics appointed Emmanuel de RIVOIRE as General Manager, effective March 27th 2017. We are very pleased to welcome Emmanuel on board. He will bring his 30+ years of managing experience in the pharmaceutical industry.
Kinnov Therapeutics (KT) is in the 2nd round of fund raising of 1.5 M Euros, after receiving 500,000 Euros. Alcoholic addiction represents a market of 140 millions patients. Read the full article in Republique du Centre – 2016/09/01 (French)
Kinnov-Therapeutics is in French magazine “Journal du Dimanche” (JDD) of 19th June 2016. Read the article in PDF.
Our composition patent, already granted in Europe, China and USA, is now also granted in Australia (31 march 2016) and Ukraine (25 april 2015).
Our composition patent, already granted in Europe and China, is now also granted in USA, since 19 january 2016.
Kinnov Therapeutics original approach to tackle alcohol addiction was recently recognized and distinguished by peers and published in the prestigious peer-reviewed PLOS One journal. This demonstrates our therapeutic strategy is based on solid scientific foundations. The Combination of Marketed Antagonists
Kinnov-Therapeutics is in French magazine Biotech Finance this month. KT wants to raise 1M€ for its Phase IIb clinical trials in alcohol addiction. Our patented drug composition is a first in class treatment of the cause of addiction. Patients recruitments